Oncimmune Holdings plc announced changes to its leadership team and its Board of Directors. As previously announced on 23 June 2023, following the divestment of Oncimmune Limited, which now allows the Company to focus on its ImmunoINSIGHTS business, Dr Adam M Hill stepped down as the Company's Chief Executive Officer and as a director of the Company. The company announced that Martin Gouldstone will be joining Oncimmune as its new Chief Executive Officer on 1 August 2023.

Martin has over 25 years of experience in the life science sector, including senior commercial roles at a major CRO and most recently as Global Senior Vice President at Owkin Inc. Martin's commercial experience and connections will be a valuable asset in driving the Company's future business development activities. Martin will also join the Company's Board of Directors and regulatory disclosures in relation to his appointment as required under Schedule 2(g) of the AIM Rules for Companies can be found at the foot of this announcement.